Chris A. Rallis - 14 Feb 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A Rallis
Issuer symbol
FENC
Transactions as of
14 Feb 2025
Net transactions value
-$8,089
Form type
4
Filing time
14 Feb 2025, 18:13:50 UTC
Previous filing
02 Dec 2024
Next filing
11 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $5,000 +1,992 +3.8% $2.51 54,206 14 Feb 2025 Direct F1
transaction FENC Common Shares Sale $8,089 -1,186 -2.2% $6.82 53,020 14 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise $5,000 -1,992 -1.1% $2.51 182,706 14 Feb 2025 Options 1,992 $2.51 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.